2Van der Linden S, van der Heijde D. Ankylosing spondylitis//Ruddy S, Harris ED Jr, Sledge CB. Kelley's textbook of rheumatology. 6th ed. Philadelphia: WB. Sannders Company, 2001:1039-1054.
3Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum, 1984, 4: 361-368.
4Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol, 1994, 12:2286-2291.
5Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the developmentof the Bath Ankylosing Spondylitis Functional Index. J Rheumatol, 1994, 12: 2281-2285.
6Dalyan M, Guner A, Tuncer S, et al. Disability in ankylosing spondylitis. Disabil Rehabil, 1999, 2: 74-79.
7Sampaio BPD, Costallat LTL, Bertolo M, et al. Methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol, 2000,3: 160-162.
8Clegg DO, Reda D J, Abdellatif M. Comparision of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestation of seronegative spendylarthropathies. Arthritis Rheum, 1999, 11: 2325-2329.
10Zochling J, Vander I-Ieijde D, Burgos-Vargas R ,et al. ASAS/EULAR rec-ommendations for the management of ankylosing spondyliti s [J]. Ann Rheum Dis, 2006,65 (4) : 442-452.
